JUN (Ab-243) Antibody

What is the specific epitope recognized by JUN (Ab-243) Antibody?

JUN (Ab-243) Antibody recognizes a synthetic peptide sequence around amino acids 241-245 (P-L-S-P-I) derived from human c-Jun . This region includes Serine 243, which is a phosphorylation site that can be important for c-Jun regulation. The antibody is designed to detect endogenous levels of total c-Jun protein . When selecting this antibody for experiments, it's important to note that it differs from phospho-specific antibodies that only recognize c-Jun when phosphorylated at specific residues like Ser243 .

What are the species reactivity profiles and applications of JUN (Ab-243) Antibody?

The JUN (Ab-243) Antibody has been validated to react with c-Jun protein from multiple mammalian species. The technical specifications indicate reactivity with:

Application compatibility varies slightly between manufacturers, but generally includes:

These dilutions provide starting points for optimization in specific experimental contexts .

What are the optimal sample preparation and protocol conditions for detecting c-Jun using Western blot?

For optimal Western blot detection of c-Jun using JUN (Ab-243) Antibody, researchers should implement the following protocol:

• Sample Preparation:

  • Use protein extraction buffers containing protease inhibitors to prevent degradation

  • For phosphorylation studies, include phosphatase inhibitors in extraction buffers

  • 293 cells have been successfully used as positive controls

  • Denature samples at 95°C for 5 minutes in reducing SDS sample buffer

• Electrophoresis and Transfer:

  • Load 20-50 μg of total protein per lane

  • Separate proteins using 10-12% SDS-PAGE gels

  • Transfer to PVDF or nitrocellulose membranes at 100V for 60-90 minutes

• Antibody Incubation:

  • Block membrane in 5% non-fat milk or 3-5% BSA in TBST for 1 hour

  • Incubate with JUN (Ab-243) Antibody at 1:500-1:1000 dilution overnight at 4°C

  • Wash 3-5 times with TBST

  • Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000-1:10000)

  • Develop using enhanced chemiluminescence

• Expected Results:

  • c-Jun appears as a band at approximately 43 kDa

  • Validate specificity by comparing with positive controls and blocking peptide experiments

This methodology has been successfully employed to detect endogenous c-Jun in cell lysates .

How can I troubleshoot weak or non-specific bands when using JUN (Ab-243) Antibody?

When encountering problems with JUN (Ab-243) Antibody in Western blotting, systematic troubleshooting can resolve most issues:

• For Weak or Absent Signal:

  • Increase protein loading (up to 50-80 μg per lane)

  • Decrease antibody dilution (try 1:250-1:500 range)

  • Extend primary antibody incubation to overnight at 4°C

  • Check antibody storage conditions; avoid repeated freeze-thaw cycles

  • Use more sensitive detection reagents (e.g., femto-level chemiluminescent substrates)

  • Verify target protein expression in your sample with positive controls (e.g., 293 cells)

• For Non-specific Bands:

  • Optimize blocking conditions (try different blockers: 5% milk, 3-5% BSA)

  • Increase washing duration and number of washes

  • Further dilute primary and secondary antibodies

  • Pre-adsorb antibody with blocking peptide to confirm specificity

  • Use gradient gels for better protein separation

  • Consider sample preparation modifications to reduce protein degradation

• For High Background:

  • Use freshly prepared buffers

  • Increase blocking time or blocker concentration

  • Ensure thorough washing between steps

  • Dilute secondary antibody further

  • Check for membrane contamination or improper handling

For validation, compare your results with established expression patterns of c-Jun in known positive sample types, and consider blocking peptide experiments to confirm specificity .

What are the recommended protocols for immunohistochemical detection of c-Jun in tissue sections?

For optimal immunohistochemical detection of c-Jun using JUN (Ab-243) Antibody, the following protocol is recommended based on validated methods:

• Tissue Preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Process and embed in paraffin

  • Section at 4-6 μm thickness onto charged slides

• Antigen Retrieval:

  • Deparaffinize sections in xylene and rehydrate through graded alcohols

  • Perform heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Heat for 15-20 minutes at 95-100°C in pressure cooker or microwave

• Immunostaining Procedure:

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum

  • Incubate with JUN (Ab-243) Antibody at 1:50-1:200 dilution

  • Incubate sections overnight at 4°C or 60 minutes at room temperature

  • Apply appropriate HRP-conjugated secondary detection system

  • Develop with DAB substrate and counterstain with hematoxylin

• Controls and Validation:

  • Include positive control tissues known to express c-Jun

  • Include a negative control by omitting primary antibody

  • For specificity validation, pre-incubate antibody with blocking peptide

This protocol has been successfully used to detect c-Jun in human breast carcinoma tissue as demonstrated in validation studies .

How should I interpret c-Jun staining patterns in different tissue and cell types?

Interpreting c-Jun staining patterns requires understanding of expected subcellular localization and expression patterns:

• Normal Subcellular Localization:

  • c-Jun is predominantly nuclear due to its function as a transcription factor

  • Nuclear staining intensity may vary depending on cell activation state

  • Some cytoplasmic staining may be observed during protein synthesis or transport

• Tissue-Specific Considerations:

  • Expression levels vary by tissue and cell type

  • Epithelial cells often show moderate to strong nuclear positivity

  • Lymphoid tissues may display variable expression depending on activation status

  • In breast carcinoma, nuclear positivity has been demonstrated with this antibody

• Quantitative Assessment:

  • Score nuclear staining intensity (negative, weak, moderate, strong)

  • Assess percentage of positive cells

  • Calculate H-score or other semi-quantitative metrics for comparison

  • Compare expression between normal and pathological tissues

• Potential Artifacts and Misinterpretations:

  • Edge artifacts may cause false positivity at tissue margins

  • Necrotic areas may show non-specific staining

  • Melanin or hemosiderin pigments can be confused with DAB positivity

  • Inadequate antigen retrieval may cause false negatives

When evaluating results, compare your staining patterns with published literature on c-Jun expression in your tissue of interest and confirm specificity using blocking peptide controls as demonstrated in validation images .

How can JUN (Ab-243) Antibody be used to study c-Jun's role in protein-protein interactions?

JUN (Ab-243) Antibody can be effectively employed to investigate c-Jun's interactions with partner proteins through several approaches:

• Co-Immunoprecipitation (Co-IP):

  • Use JUN (Ab-243) Antibody at 1:50-1:200 dilution for immunoprecipitation

  • Pre-clear lysates with appropriate control IgG

  • Capture antibody-antigen complexes with Protein A/G beads

  • Analyze precipitated complexes by Western blotting for potential binding partners

  • This approach can identify interactions with other AP-1 family members, co-factors, or regulatory proteins

• Chromatin Immunoprecipitation (ChIP):

  • Use JUN (Ab-243) Antibody to immunoprecipitate c-Jun cross-linked to chromatin

  • Analyze DNA fragments to identify genomic binding sites

  • This can reveal direct transcriptional targets of c-Jun

• Proximity Ligation Assay (PLA):

  • Combine JUN (Ab-243) Antibody with antibodies against suspected interaction partners

  • Visualize protein-protein interactions in situ with single-molecule resolution

  • Quantify interaction events in different cellular compartments

• Immunofluorescence Co-localization:

  • Use JUN (Ab-243) Antibody in combination with antibodies against other proteins

  • Analyze spatial overlap to infer potential interactions

  • Particularly useful for studying dynamic changes in protein complexes

When designing these experiments, researchers should consider the accessibility of the epitope (aa.241-245) in protein complexes to ensure the antibody can recognize c-Jun in its native interaction state.

What are the considerations for using JUN (Ab-243) Antibody in studies of phosphorylation-dependent signaling?

When investigating phosphorylation-dependent signaling involving c-Jun, researchers should consider several important factors when using JUN (Ab-243) Antibody:

• Epitope Accessibility and Phosphorylation State:

  • JUN (Ab-243) Antibody recognizes the region around Serine 243

  • This antibody likely detects total c-Jun regardless of phosphorylation status at Ser243

  • For phosphorylation-specific detection, researchers should use Anti-phospho-JUN (pSer243) antibody

• Experimental Design for Phosphorylation Studies:

  • Use complementary antibodies to distinguish between total and phosphorylated c-Jun:

    • JUN (Ab-243) Antibody for total c-Jun levels

    • Phospho-specific antibodies for activation state

  • Include appropriate controls for phosphatase treatment

  • Preserve phosphorylation status during sample preparation by using phosphatase inhibitors

• Analytical Approaches:

  • Western blotting with parallel detection of total and phospho-c-Jun

  • Immunoprecipitation with JUN (Ab-243) followed by phospho-specific detection

  • Immunohistochemistry comparison of serial sections stained with total and phospho-specific antibodies

• Stimulus-Response Experiments:

  • Monitor c-Jun phosphorylation kinetics after cellular stimulation

  • Compare total c-Jun levels (using JUN (Ab-243)) with phosphorylation changes

  • Correlate phosphorylation with downstream transcriptional activity

By using JUN (Ab-243) Antibody in combination with phospho-specific antibodies, researchers can gain a comprehensive understanding of c-Jun regulation through phosphorylation events.

How does the structure of antibody complementarity-determining regions influence c-Jun epitope recognition?

The recognition of c-Jun epitopes by antibodies like JUN (Ab-243) is fundamentally influenced by the structure and properties of the antibody's complementarity-determining regions (CDRs):

• CDR Structure and Epitope Recognition:

  • Antibodies contain six CDRs (three from heavy chain, three from light chain)

  • CDR-H3 typically displays the greatest variability in length and sequence diversity

  • CDR-H3 often plays a primary role in antibody-antigen interactions

  • For recognition of the c-Jun epitope (aa.241-245), the conformation of these CDRs creates a binding pocket complementary to the PLSPI sequence

• Canonical Structures in Epitope Binding:

  • Five of the six CDRs tend to adopt limited conformational patterns called "canonical structures"

  • These conformations are determined by loop length and amino acid composition

  • The specific canonical structures in JUN (Ab-243) Antibody likely create an optimal binding interface for the c-Jun epitope

  • Variations in these structures between different c-Jun antibodies explain their epitope specificities

• Considerations for Epitope Accessibility:

  • The peptide sequence used to generate JUN (Ab-243) Antibody (PLSPI) must be accessible in the properly folded c-Jun protein

  • This accessibility may change depending on:

    • Protein conformation changes

    • Post-translational modifications

    • Protein-protein interactions

    • Protein-DNA binding

• Implications for Antibody Engineering:

  • Understanding the CDR-epitope interaction can guide rational design of improved c-Jun antibodies

  • Computational and rational design approaches can enhance antibody affinity through targeted mutations

  • Single-chain antibody fragments derived from JUN (Ab-243) could be engineered for specialized applications

The structural basis of c-Jun recognition by JUN (Ab-243) Antibody underscores the importance of epitope selection in antibody development and explains the specificity profile observed in validation studies.

How should I design experiments comparing multiple c-Jun antibodies targeting different epitopes?

When conducting comparative studies using multiple c-Jun antibodies, including JUN (Ab-243), careful experimental design is essential:

• Strategic Selection of Antibodies:

  • Choose antibodies targeting distinct epitopes across the c-Jun protein:

    • N-terminal region (transactivation domain)

    • DNA-binding domain

    • Leucine zipper domain

    • C-terminal region (including Ab-243 region)

  • Include both phospho-specific and total protein antibodies

  • Consider antibodies from different host species to facilitate co-staining

• Validation and Cross-comparison Protocol:

  • Perform parallel Western blots with standardized conditions

  • Run immunohistochemistry on serial sections

  • Use identical sample preparation and detection methods

  • Include shared positive and negative controls

  • Implement blocking peptide controls for each antibody

• Quantitative Comparison Framework:

  • Standardize signal quantification methods

  • Use recombinant c-Jun standards of known concentration

  • Calculate detection limits and linear range for each antibody

  • Assess reproducibility across technical and biological replicates

• Application-specific Considerations:

  • For protein interactions: Test which antibodies might interfere with protein complexes

  • For phosphorylation studies: Compare epitope accessibility in different activation states

  • For chromatin studies: Evaluate which antibodies work effectively in fixed chromatin

• Systematic Documentation:

  • Record lot numbers and concentrations

  • Document all protocol variations

  • Maintain standardized scoring for qualitative assessments

This approach enables researchers to identify the most suitable antibody for each specific application and to understand how epitope location affects experimental outcomes.

What controls should be implemented when using JUN (Ab-243) Antibody in critical research applications?

Rigorous control strategies are essential when using JUN (Ab-243) Antibody in research applications:

• Specificity Controls:

  • Peptide Competition: Pre-incubate antibody with immunizing peptide (PLSPI sequence)

  • Genetic Controls: Use c-Jun knockout/knockdown models where available

  • Multiple Antibody Validation: Compare with antibodies targeting different c-Jun epitopes

• Technical Controls:

  • Loading Controls: Include appropriate housekeeping proteins in Western blots

  • Isotype Controls: Use non-specific rabbit IgG at equivalent concentration

  • Procedural Controls: Omit primary antibody but maintain all other steps

  • Staining Controls: Include known positive and negative tissues in IHC

• Application-Specific Controls:

  • Western Blot: Include recombinant c-Jun protein or validated positive control lysate (e.g., 293 cells)

  • IHC: Process serial sections with different antibodies and blocking controls

  • IP: Perform parallel IP with non-specific IgG to identify non-specific binding

• Quantitative Controls:

  • Standard Curves: Use purified protein standards for quantification

  • Dilution Series: Perform serial dilutions to confirm linear detection range

  • Reproducibility Checks: Include internal reference samples across experiments

• Documentation of Antibody Information:

  • Record catalog number, lot number, and dilution used

  • Document storage conditions and handling

  • Note any deviations from manufacturer recommendations